Navigation Links
Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
Date:3/20/2013

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib, the study shows.

Results of this study appear in the March issue of Leukemia Research.

Myelodysplastic syndromes are disorders of the stem cell in bone marrow. The marrow does not produce enough normal blood cells for the body. As the number of quality blood-forming cells declines, blood production is impaired.

According to the researchers, stem cell transplantation is the only potentially curative option for MDS but also has risks of morbidity and mortality. A class of medication called azanucleosides is the only approved medication for patients with an advanced stage of this disease. The outcome after failure of azanucleosides is poor. Therefore, new therapies for MDS are needed, said the study authors.

Dasatinib, a multikinase inhibitor, has been approved by the Food and Drug Administration for patients with chronic myelogenous leukemia. The drug has promising potential because of its activity against a broad spectrum of tyrosine kinases, which are enzymes that function as an 'on' or 'off' switch for many cellular functions, such as increased activation of cell migration, proliferation, survival, invasion and angiogenesis (tumor blood vessel growth).

"This phase II trial was to assess whether dasatinib would be beneficial for patient with higher risk MDS whose previous treatments had failed," said study corresponding author Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies and member of the Chemical Biology and Molecular Medicine Program at Moffitt. "We found that while dasatinib was well-tolerated with limited toxicities, it only had modest activity."

Among 18 patients treated, three patients responded, four had stable disease, and 10 experienced disease progression. They also noted that four of the five participants with trisomy 8, a disorder caused by having three copies of chromosome 8, had stable disease. An observation, they concluded, warrants further investigation.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Cancer doesnt change young girls desire to have children, Moffitt Cancer Center study shows
2. Surgery and radiation improve survival for metastatic gastric cancer patients, Moffitt study shows
3. Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
4. Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
5. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
6. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
7. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
8. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
9. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
10. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
11. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology: